Company profile
Ticker
CTNM
Exchange
Employees
Incorporated
Fiscal year end
Industry (SIC)
SEC CIK
IRS number
271467257
CTNM stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
20 May 24
10-Q
2024 Q1
Quarterly report
16 May 24
8-K
Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
16 May 24
8-K
Amendments to Articles of Incorporation or Bylaws
9 Apr 24
S-8
Registration of securities for employees
9 Apr 24
424B4
Prospectus supplement with pricing info
5 Apr 24
EFFECT
Notice of effectiveness
5 Apr 24
CERT
Certification of approval for exchange listing
4 Apr 24
8-A12B
Registration of securities on exchange
2 Apr 24
S-1/A
IPO registration (amended)
1 Apr 24
Latest ownership filings
3
Troy A. Ignelzi
20 May 24
4
Troy A. Ignelzi
20 May 24
SC 13G
SUVRETTA CAPITAL MANAGEMENT, LLC
15 Apr 24
SC 13G
PERCEPTIVE ADVISORS LLC
15 Apr 24
4
Change in insider ownership
11 Apr 24
SC 13G
JOHNSON & JOHNSON
10 Apr 24
3
& JOHNSON JOHNSON
10 Apr 24
3
Initial statement of insider ownership
4 Apr 24
3
Olivia C Ware
4 Apr 24
3
Evert B. Schimmelpennink
4 Apr 24
Financial summary
Quarter (USD) | Mar 24 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 16.26 mm | 16.26 mm | ||||
Cash burn (monthly) | 3.31 mm | 2.66 mm | ||||
Cash used (since last report) | 5.59 mm | 4.49 mm | ||||
Cash remaining | 10.68 mm | 11.78 mm | ||||
Runway (months of cash) | 3.2 | 4.4 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 May 24 | Troy A. Ignelzi | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 15.71 | 23,150 | 363.69 k | 23,150 |
9 Apr 24 | Versant Venture Capital VI | Class A Common Stock | Conversion | Acquire C | Yes | No | 0 | 148,312 | 0.00 | 148,312 |
9 Apr 24 | Versant Venture Capital VI | Class A Common Stock | Conversion | Acquire C | Yes | No | 0 | 2,531 | 0.00 | 2,531 |
9 Apr 24 | Versant Venture Capital VI | Class A Common Stock | Conversion | Acquire C | Yes | No | 0 | 391,785 | 0.00 | 391,785 |
9 Apr 24 | Versant Venture Capital VI | Series C Preferred Stock Class B Common Stock | Conversion | Acquire C | Yes | No | 0 | 275,769 | 0.00 | 710,494 |
9 Apr 24 | Versant Venture Capital VI | Series C Preferred Stock Class B Common Stock | Conversion | Acquire C | Yes | No | 0 | 689 | 0.00 | 12,123 |
9 Apr 24 | Versant Venture Capital VI | Series C Preferred Stock Class B Common Stock | Conversion | Acquire C | Yes | No | 0 | 110,187 | 0.00 | 1,934,776 |
9 Apr 24 | Versant Venture Capital VI | Series B Preferred Stock Class B Common Stock | Conversion | Acquire C | No | No | 0 | 317,988 | 0.00 | 1,741,107 |
9 Apr 24 | Versant Venture Capital VI | Series B Preferred Stock Class B Common Stock | Conversion | Acquire C | Yes | No | 0 | 434,725 | 0.00 | 434,725 |
9 Apr 24 | Versant Venture Capital VI | Series B Preferred Stock Class B Common Stock | Conversion | Acquire C | Yes | No | 0 | 2,182 | 0.00 | 11,434 |
News
Stifel Initiates Coverage On Contineum Therapeutics with Buy Rating, Announces Price Target of $29
30 Apr 24
Morgan Stanley Initiates Coverage On Contineum Therapeutics with Overweight Rating, Announces Price Target of $25
30 Apr 24
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
16 Apr 24
UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
16 Apr 24
Contineum Therapeutics, Inc To Start Trading Tomorrow
4 Apr 24